Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead
Shares of Boston Scientific Corp dropped roughly 4% Thursday following its deal to acquire blood-clot treatment company Penumbra. Boston Scientific's stock slipped $3.75, closing near $90.03 in late U.S. trading. Meanwhile, Penumbra surged around 12%, reaching $350.49.